Vijaya Diagnostic Centre Ltd

Dr. Manjula Anagani – Independent Director

• Dr. Manjula Anagani, Independent Director, ceased due to tenure completion; no other material reasons; effective Aug 21, 2026.

Resolutions and outcomes

• Appointment of Satyanarayana Murthy Chavali as Independent Director—Special; approved with 99.9995% in favour.
• Appointment of Dipinder Singh Sekhon as Independent Director—Special; approved with 99.9995% in favour.
• Overall outcome: All postal ballot resolutions passed with requisite majority.

AGM Details

• 24th AGM scheduled for Sep 24, 2026 at 11:00 IST via VC/OAVM.

Record Date & Dividend Entitlement

• Record date for dividend entitlement fixed as Sep 16, 2026.
• Dividend, if declared, will be paid within statutory timelines.

Voting Timelines

• Remote e-voting opens Sep 21, 2026, 9:00 AM to Sep 23, 2026, 5:00 PM.
• Cut-off date for voting and entitlement is Sep 16, 2026.

Financial Performance

• Q1 FY27 consolidated revenue stood at ~Rs. 231 crores, up 22.8% YoY.
• Growth driven by test volume up 16.5% YoY and mix/realization changes.
• Hyderabad revenue grew 17% YoY; Pune grew 18% YoY.
• Geography mix: Hyderabad 67%, Rest of AP-Telangana 20%, Pune 6%, West Bengal 4%, others 3%.
• B2C revenue stood healthy at 92%; radiology contribution 37%.
• Revenue per test INR 503; revenue per footfall INR 1,860.
• EBITDA for the quarter was INR 98 crores; margin 42.7% (up 360 bps YoY).
• PAT stood at INR 53 crores; PAT margin 23%.
• Capex plan: 9 hubs, 10–12 spokes, Panjagutta lab; land in AP for hub INR 8–10 crores.
• Total expansion capex expected at INR 190–195 crores.
• Surplus cash approximately INR 330 crores; cash PAT generation around 26–27%.
• Pathology revenues scaling; hub expansion strategy to deepen presence.

Operations & Capacity

• 166 centers as of Q1: 51 hubs, 115 spokes, ~26 processing units.
• Two hubs commissioned this quarter: Bengaluru JP Nagar (₹30 cr) and Hyderabad Gachibowli (₹9 cr).
• Pune revenue rose from ₹10.8 cr to ₹12.8 cr; growth ~18% YoY.
• PH Diagnostic Pune acquisition: 12 collection centres upgraded with imaging & cardiology.
• AP hub land purchase planned; capex includes JP Nagar ₹30 cr and Gachibowli ₹9 cr.
• Panajgutta reference laboratory capex included in overall capex plan.
• Mature centers grew 16%; new centers contributed 6–6.5% of quarterly revenue.
• Burn from 3–4 hubs not yet breakeven ~0.5% of top line; overall no burn for 10 hubs.
• Wellness share ~15% of revenue; premium packages ₹8,000–₹10,000; limited discounts.
• AI smart reports integrated with wellness packages; clinical use requires testing/certification.

Pricing & Competitive Landscape

• Last price hike was June 2025; limited to Hyderabad tests; pricing to be reassessed post Q2/Q3.
• Bangalore competition steady; Vijaya holds larger market share; no strong intensity in Hyderabad.
• Wellness packages spanning basic tests to full imaging; differentiated by in-house cardiology expertise.

Balance Sheet & Cash

• Surplus cash ~₹330 crores; sustained cash PAT generation around 26–27%.

Outlook & Guidance

• Next 12 months: 9 hubs and 10–12 spokes; Panjagutta lab; land purchase in AP.
• Total expansion capex guided at ₹190–195 crores.
• EBITDA margin target around 40–45%; Q1 margin was 42.5%; drag 0.5–1.5 pp possible.
• FY27 growth expected to be in high double digits; 3–5 year CAGR around 15%.
• Expansion will be phased; fixed-cost base supports margins; hub-level breakevens achieved.

Fractional entitlements distribution

• Audit Committee certifies distribution of proceeds to eligible shareholders from sale of 3,914 fractional entitlements.
• Sale of fractional entitlements occurred on 22 June 2026.
• Proceeds distributed via banking mode on 5 August 2026.
• Unpaid amounts remain in escrow due to unavailable bank details.
• Escrow account with HDFC Bank for fractional shares: account number 50200118300305.
• Total amount payable to eligible shareholders: INR 5,184,902.83.
• Paid to shareholders: INR 1,499,575.21.
• Unpaid/escrowed: INR 3,685,326.84.
• VDCL to trace bank details; untraceable funds go to IEPF after seven years.
• Independent Directors certify distribution aligns with SEBI Master Circular and Scheme provisions.

Meeting Details

• Date and time: 12 August 2026, 09:00–17:00 IST.
• Type/Mode: Group and one-on-one meetings, in-person.
• Event/Organizer: EMKAY Confluence 2026 - Annual Investor Conference.
• Venue: Mumbai.

Participants

• Key company participants: officials attending; includes Company Secretary & Compliance Officer.
• Other officials may participate per schedule.

Purpose

• Purpose: General investor interaction at EMKAY Confluence 2026; discussions based on public information.

Meeting Details

• Date and time: Friday, Aug 7, 2026 at 10:30 IST
• Type: earnings conference call; Mode: virtual
• Event: Q1FY27 earnings conference call; organiser: JM Financial Institutional Securities Limited
• Dial-in details enclosed

Participants

• MD & CEO present
• COO present
• CFO present
• Head – Investor Relations & Corporate Development present

Purpose

• Discuss Q1 FY27 results with analysts/investors

Meeting Details

• Board meeting scheduled for August 6, 2026; time and venue not disclosed.

Key Agenda Items

• Standalone and consolidated unaudited financial results for the first quarter ended June 30, 2026.
• Other corporate matters.

Other Notes

• Trading window closed for designated persons and their immediate relatives from July 1, 2026 to August 8, 2026.